D. E. Shaw & Co., Inc. Fulgent Genetics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 134,928 shares of FLGT stock, worth $2.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,928

Previous 40,695 231.56%

Holding current value

$2.69 Million

Previous $1.18 Million 148.89%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$21.55 - $29.29 $2.03 Million - $2.76 Million	94,233 Added 231.56%	134,928 $2.93 Million
Q4 2023 Feb 14, 2024	SELL	$23.64 - $30.27 $60,234 - $77,127	-2,548 Reduced 5.89%	40,695 $1.18 Million
Q3 2023 Nov 14, 2023	SELL	$26.74 - $40.81 $36,099 - $55,093	-1,350 Reduced 3.03%	43,243 $1.16 Million
Q2 2023 Aug 14, 2023	SELL	$28.52 - $40.7 $981,059 - $1.4 Million	-34,399 Reduced 43.55%	44,593 $1.65 Million
Q1 2023 May 15, 2023	BUY	$29.39 - $36.27 $1.25 Million - $1.54 Million	42,496 Added 116.44%	78,992 $2.47 Million

Q4 2022 Feb 14, 2023	BUY	$29.23 - $40.28 $293,059 - $403,847	10,026 Added 37.88%	36,496 $1.09 Million
Q3 2022 Nov 14, 2022	BUY	$37.92 - $63.74 $222,590 - $374,153	5,870 Added 28.5%	26,470 $1.01 Million
Q2 2022 Aug 15, 2022	BUY	$47.98 - $62.75 $427,022 - $558,475	8,900 Added 76.07%	20,600 $1.12 Million
Q1 2022 May 16, 2022	BUY	$49.85 - $96.11 $583,245 - $1.12 Million	11,700 New	11,700 $730,000
Q2 2021 Aug 16, 2021	SELL	$66.8 - $100.45 $394,454 - $593,157	-5,905 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$59.3 - $183.85 $350,166 - $1.09 Million	5,905 New	5,905 $571,000

Others Institutions Holding FLGT

# of Institutions

199

Shares Held

14.7M

Call Options Held

1.16M

Put Options Held

92.9K

View Full List

About Fulgent Genetics, Inc.

Ticker FLGT
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,265,800
Market Cap $603M
Description
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...

More about FLGT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account